Using a centralised interactive voice response system , we randomly assigned ( @:@:@ ) patients in a block size of six to receive intravenous pembrolizumab @ mg/kg or @ mg/kg every @ weeks or investigator-choice chemotherapy ( paclitaxel plus carboplatin , paclitaxel , carboplatin , dacarbazine , or oral temozolomide ) .